Generex adds prostate cancer patients to Antigen Express cancer vaccine trials

By Elaine Rigoli

Tampa, Fla., Aug. 8 - Generex Biotechnology Corp. said Tuesday that it has entered into an agreement with the Euroclinic in Athens, Greece to begin clinical trials on a novel immunotherapeutic vaccine being developed by its wholly owned subsidiary, Antigen Express, Inc.

The compound has been in clinical trials for more than a year at the Walter Reed Army Medical Center in Washington, D.C., in patients with breast cancer and has shown good immune stimulatory activity, Generex said.

Because of these positive results, the company said it decided to expand studies into patients with prostate cancer.

The new prostate cancer studies will include 30 patients and will focus on immunological responsiveness to a dose of the vaccine previously shown to be well-tolerated in breast cancer patients.

Imaging studies to monitor disease progression will be performed at the end of the six-month course of therapy or earlier should there be indications of therapeutic benefit.

Toronto-based Generex develops drug-delivery systems and technologies. Antigen Express develops proprietary vaccine formulations and is based in Worcester, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.